Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Wyeth announces major adult vaccine trial

Wyeth announces major adult vaccine trial

25th September 2008

Wyeth Pharmaceuticals, a division of Wyeth, has announced the start of a study of an investigational 13-valent conjugate vaccine that aims to prevent pneumococcal pneuomonia.

Around 85,000 patients are expected to enrol in the phase IV Community Acquired Pneumonia Immunisation Trial in agreement with the US Food and Drug Administration, with the results not intended for inclusion in the company’s currently planned regulatory filing for the vaccine.

Wyeth noted pneumococcal pneumonia is the most commonly community acquired bacterial pneumonia in the US and Europe, with adult mortality rate of between ten and 20 per cent, rising to over 50 per cent in high-risk groups across the globe.

Marc Bonten, professor of molecular epidemiology of infectious diseases at the department of medical microbiology at the Julius Centre for Health Sciences and Primary Care at the University Medical Centre in Utrecht, said: “We are very excited to conduct this major trial addressing the important disease of adult pneumonia.”

He added the main goal of the trial is to assess the effectiveness of the vaccine in preventing the onset of the disease caused by the serotypes included in the vaccine, while it will also evaluate its efficacy in preventing all-cause pneumonia and invasive pneumococcal disease.

In May 2008, Wueth said patients with community-acquired pneumonia may soon be treated with Tygacil (tigecycline).

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.